As part of the plan, Amazon has agreed to purchase 100,000 electric delivery vans from vehicle manufacturer Rivian.Technologyread more
Vice President Pence's sit-down with CNBC's Joe Kernen comes as President Donald Trump's White House navigates a forest of thorny political issues.Delivering Alpharead more
The plan will allow Medicare to negotiate lower prices on as many as 250 drugs and apply those discounts to private health plans.Health and Scienceread more
President Donald Trump on Thursday filed a lawsuit against Manhattan District Attorney Cyrus Vance Jr. and his longtime accounting firm Mazars.Politicsread more
The Democratic-held House plans to move forward with a bill to fund the government through Nov. 21 and avoid another government shutdown.Politicsread more
Jim Chanos, founder of Kynikos Associates, revealed Thursday a stock he has been shorting for years: kidney dialysis company DaVita.Delivering Alpharead more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
The U.S. economy will have a tough time at the start of 2020, says the head of one of the largest bond managers in the world.Delivering Alpharead more
The Federal Reserve has calmed the overnight funding market and brought its fed funds rate back in line with its target.Market Insiderread more
Forecasters say Hurricane Jerry could pass just north of the Leeward Islands on Friday, then move between Puerto Rico and the Bahamas on Saturday and Sunday.Weather & Natural Disastersread more
Sept 10 (Reuters) - Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.
Shares of Lexicon jumped 37.8% to $2.37 in after hours trading.
Under the terms of the settlement, Sanofi will pay $208 million upfront and the remainder within twelve months to Lexicon, which was eligible to receive up to $1.4 billion in milestone payments under the partnership.
The four-year partnership was terminated by Sanofi in July after the results of three late-stage studies of Zynquista, which is being developed as an add-on to insulin for diabetic patients.
Lexicon will regain global rights for the development and commercialization of Zynquista in both type 1 and type 2 diabetes, the company said in a statement.
The drug has been approved in the European Union for use in type 1 diabetic patients but failed to win U.S. approval in March, months after a panel of experts raised concerns of the risk of diabetic ketoacidosis (DKA).
DKA is a life-threatening condition in which acids called ketones build up when the body starts to use fat instead of glucose as a source of energy. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber)